Quantinno Capital Management LP Has $650,000 Holdings in Omeros Corporation $OMER

Quantinno Capital Management LP increased its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 145.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,541 shares of the biopharmaceutical company’s stock after acquiring an additional 36,467 shares during the period. Quantinno Capital Management LP’s holdings in Omeros were worth $650,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMER. Acadian Asset Management LLC acquired a new position in Omeros in the first quarter worth $357,000. XTX Topco Ltd acquired a new stake in shares of Omeros in the second quarter valued at $191,000. Invesco Ltd. increased its stake in shares of Omeros by 34.1% in the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 29,644 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. bought a new position in shares of Omeros in the second quarter valued at about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Up 7.0%

Omeros stock opened at $18.39 on Thursday. The business’s 50-day simple moving average is $11.35 and its 200 day simple moving average is $11.66. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 14.37 and a beta of 2.54. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $18.89.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. As a group, sell-side analysts expect that Omeros Corporation will post -0.37 EPS for the current year.

Insider Buying and Selling

In other Omeros news, CAO David J. Borges sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total value of $84,750.00. Following the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $84,750. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the sale, the director directly owned 35,067 shares of the company’s stock, valued at $407,127.87. This represents a 17.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on OMER. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.